Positive prognostic impact of miR-210 in non-small cell lung cancer

详细信息    查看全文

• 作者：Marte Eilertsen ; Sigve Andersen ; Samer Al-Saad ; Elin Richardsen ; Helge Stenvold ; Sigurd M. Hald ; Khalid Al-Shibli ; Tom Donnem ; Lill-Tove Busund ; Roy M. Bremnes
• 关键词：NSCLC ; Prognosis ; miR-210 ; Tumor stromal cells ; Cancer cells ; Biomarker
• 刊名：Lung Cancer
• 出版年：February, 2014
• 年：2014
• 卷：83
• 期：2
• 页码：272-278
• 全文大小：1511 K

文摘

Objectives

miR-210 is an important regulator of the cellular response to hypoxia. Therefore, we aimed to explore the prognostic significance of miR-210 in non-small cell lung cancer (NSCLC) patients with stage I-IIIA disease.

Materials and methods

In addition to clinicopathological and demograpic information, tumor tissues were collected and tissue micro arrays (TMAs) were constructed from 335 patients with stage I-IIIA NSCLC. Expression of miR-210 in cancer cells and stromal cells of the tumor was assessed by in situ hybridization.

Results

In univariate analyses, high cancer cell (p = 0.039) and high stromal cell expression (p = 0.008) of miR-210 were both significantly associated with an improved disease-spesific survival (DSS). High co-expression of miR-210 in cancer and stromal cells was also a positive prognostic factor for DSS (p = 0.010). In multivariate analysis, miR-210 in stromal cells (p = 0.011), and miR-210 co-expressed in cancer and stromal cells was an independent prognosticator for DSS (p = 0.011).

Conclusions

We show that miR-210 in stromal cells, and co-expressed in cancer cells and stromal cells mediates an independent prognostic impact. It is a candidate marker for prognostic stratification in NSCLC.